Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: Yahoo! Finance
Net loss: US$9.99m (down by 156% from US$17.9m profit in FY 2022). US$0.46 loss per share (down from US$0.90 profit in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period Ocuphire Pharma Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 84%. Looking ahead, revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 21% from a week ago. Risk Analysis Before you take the next step you should know about the 2 warning signs for Ocuphire Pharma that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We
Show less
Read more
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingGlobeNewswire
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]Yahoo! Finance
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryGlobeNewswire
- Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisGlobeNewswire
OCUP
Earnings
- 11/13/23 - Beat
OCUP
Sec Filings
- 4/19/24 - Form PRE
- 4/17/24 - Form 8-K
- 4/15/24 - Form 4
- OCUP's page on the SEC website